Shire news

11 Mar 2010 Director/PDMR Shareholding
09 Mar 2010 Director/PDMR Shareholding
05 Mar 2010 Director/PDMR Shareholding
04 Mar 2010 District Court Upholds FDA’s Grant of 5-Year Market Exclusivity to VYVANSE®
03 Mar 2010 Director/PDMR Shareholding
03 Mar 2010 Director/PDMR Shareholding
02 Mar 2010 Supplementary Reporting Announcement
01 Mar 2010 Elections for Interim Dividend in Respect of the Six Months to December 31, 2009
01 Mar 2010 Total Voting Rights
01 Mar 2010 March is Kidney Health Month
01 Mar 2010 Mars est le mois de la santé rénale
26 Feb 2010 Shire Announces FDA Approval of VPRIV™ (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
26 Feb 2010 FDA Press Release - FDA Approves Therapy to Treat Gaucher Disease
26 Feb 2010 Shire Supports Rare Disease Day 2010
24 Feb 2010 Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL® (agalsidase alfa) with the U.S. Food and Drug Administration (FDA)
19 Feb 2010 Excellent results in a transformational year for Shire; core product sales up 25%
11 Feb 2010 Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naïve Patients with Type 1 Gaucher Disease
04 Feb 2010 Full Year 2009 results date notification – 19 February 2010
03 Feb 2010 Shire to Present Important Study Findings for Gaucher Disease Treatment and GLD Development Program at the Lysosomal Disease Network (LDN) World Symposium
01 Feb 2010 VYVANSE® — new ADHD treatment option — now available in Canada
01 Feb 2010 Total Voting Rights
26 Jan 2010 Notification of major interests in shares
18 Jan 2010 Directorate Change
04 Jan 2010 Total Voting Rights

Did you know...

We have developed a
version of this web site
that is suitable for your
portable device.

Related links

Our strategy
Corporate Governance
Media